What the FDA labels say about taking them together
Oxymorphone and pregabalin
Oxymorphone's FDA label of June 29, 2026 names pregabalin in its drug interactions section; pregabalin's label does not name oxymorphone itself but warns about its class (Opioids (opioid agonists)).
Check it at the source: the oxymorphone FDA label on DailyMed (effective June 29, 2026, Aurolife Pharma, LLC); the pregabalin FDA label on DailyMed (effective April 15, 2025, Viatris Specialty LLC).
What does the oxymorphone label say about pregabalin?
Oxymorphone label, drug interactionsExamples; Benzodiazepines and other sedatives/hypnotics, anxiolytics tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol.
Oxymorphone label, warnings and precautionsProfound sedation, respiratory depression, coma, and death may result from the concomitant use of oxymorphone hydrochloride tablets with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [ gabapentin or pregabalin] other opioid.
Source: FDA drug label (Oxymorphone Hydrochloride), Aurolife Pharma, LLC, effective June 29, 2026 (SPL set 22c7652a-aa16-4fa8-89d9-517e69059068), via openFDA; the full label on DailyMed
What does the pregabalin label say about oxymorphone?
Pregabalin's label does not name oxymorphone itself; it warns about its class (Opioids (opioid agonists)):
Pregabalin label, warnings and precautionsThere is evidence from case reports, human studies, and animal studies associating LYRICA with serious, life-threatening, or fatal respiratory depression when co-administered with central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.
Pregabalin label, warnings and precautionsWhen the decision is made to co-prescribe LYRICA with another CNS depressant, particularly an opioid, or to prescribe LYRICA to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating LYRICA at a low dose.
Source: FDA drug label (Lyrica), NDA021446 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2025 (SPL set d4734e7d-5079-455e-8ff5-8f4539c998a9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oxymorphone | Pregabalin | |
|---|---|---|
| Labeled for | Pain | Nerve pain and fibromyalgia, Seizures and epilepsy |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0571 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once